Don't miss this opportunity.
Amarantus Bioscience - AMBS - Currently trading under a dime. Market cap of $50M with five pipeline assets each of which could be worth many times the current M.C.
Strong position in Alzheimer's diagnostics. Patented drug, MANF, already has four orphan indications and one designation.
Zacks' bio-tech analyst Jason Napadano has a buy rating on the stock and believes it's worth almost four times its current valuation.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's B.O.D. and believes it could be another Amgen.
1,000% at any time is possible.
Silicon Valley based company with substantial industry contacts.
5-10 bagger this year.